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ABSTRACT

Polycyclic aromatic hydrocarbons (PAHs) and arsenic are both toxic contaminants that
are widely distributed in the environment. Previous studies have shown that certain levels of
PAHs and arsenic exposure individually can lead to immune suppression and carcinogenesis.
Co-exposures to these two classes of chemicals are commonly seen in the environment.
However, no previous studies have evaluated the immunotoxicity following simultaneous
exposure to both arsenic and PAHs. Therefore, the purpose of this study was to define the
immunotoxicity of selected PAHs and arsenic in a murine spleen cell system, and to elucidate
possible toxicological mechanisms.
Spleen cells were isolated from male C57BL/6J wild-type mice and treated with PAHs
and/or arsenic. The immunotoxicological assay used in this study was the T-dependent antibody
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response (TDAR) to sheep red blood cells (SRBC), measured by a direct plaque forming cell
(PFC) assay. Cell viability was examined using trypan blue staining. Spleen cell viability was not
altered following four days of PAHs and/or arsenic in vitro treatment compared to vehicle
control. However, the TDAR demonstrated that the IgM antibody response was suppressed by
both PAHs and arsenic in a dose-dependent manner. The PAHs and certain metabolites,
including benzo[a]pyrene (BaP), BaP-7,8- diol, benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE),
7,12-dimethylbenz[a]anthracene (DMBA), DMBA-3,4-diol, dibenzo[a,l]pyrene (DB[a,l]P). PAH
metabolites were found to be more potent than parent compounds in producing
immunosuppression. Interestingly, DB[a,l]P, a recently discovered potent carcinogenic PAH,
was found to be strongly immunosuppressive following in vitro exposures. Sodium arsenite
(As3+) was found to be more potent than sodium arsenate (As5+) in suppressing the TDAR. In
addition, combination treatments of PAHs and arsenic at low doses exhibited significantly
greater immunosuppressive effects than PAHs by themselves, suggesting that arsenic potentiates
PAH immunosuppression. Further evidence from Western blots revealed that PAHs and As3+
both triggered a p53 protein up-regulation or stabilization. Combined low dose exposure of
PAHs and As3+ demonstrated an additive p53 response that was stronger than individual
treatment with PAHs or As3+.
Taken together, these studies demonstrated that PAHs and arsenic suppress the TDAR in
spleen cells from C57BL/6J wild-type mice, and low-dose combinations of these chemicals
produced synergistic immunosuppression in vitro. We also demonstrated a potential role for p53
in both PAHs and arsenic induced immunotoxicity.

VI

TABLE OF CONTENTS

ABSTRACT.................................................................................................................................. V
LIST OF FIGURES .................................................................................................................VIII

INTRODUCTION......................................................................................................................... 1
HYPOTHESIS AND SPECIFIC AIMS.................................................................................... 13
MATERIALS AND METHODS ............................................................................................... 15
RESULTS .................................................................................................................................... 20
DISCUSSION .............................................................................................................................. 41
LIST OF ABBRVIATIONS ....................................................................................................... 50
REFERENCES............................................................................................................................ 53

VII

LIST OF FIGURES

Figure 1. Chemical Structures of Selected PAHs. .......................................................................... 3
Figure 2. Schematic of Benzo[a]pyrene Metabolic Activation ...................................................... 4
Figure 3. Schematic for DMBA metabolism and the formation of the ultimate genotoxic
metabolite of DMBA, DMBA-DE............................................................................................ 6
Figure 4. Schematic of Dibenzo[a,l]pyrene Metabolic Activation Pathways................................. 7
Figure 5. Known Structures and Metabolic Pathways of Arsenate in Vertebrates....................... 10
Figure 6. DMBA and DMBA-diol Suppress the Spleen Cell TDAR in C57BL/6J mice............. 21
Figure 7. Immunosuppressive Effect of DB[a,l]P on the Spleen Cell TDAR in C57Bl/6J mice. 23
Figure 8. Immunosuppressive Effect of BaP, BaP-diol and BPDE on the Spleen Cell TDAR in
C57BL/6J mice. ...................................................................................................................... 25
Figure 9. Immunosuppressive Effects of As3+ and As5+ on the Spleen Cell TDAR in C57Bl/6J
mice......................................................................................................................................... 27
Figure 10. Immunosuppressive Effect of Co-exposure to As3+ and DMBA-diol on C57Bl/6J mice
Splenocytes TDAR. ................................................................................................................ 29
Figure 11. Immunosuppressive Effect of Combining As3+ and DB[a,l]P on C57Bl/6J mice
Splenocytes TDAR. ................................................................................................................ 31
Figure 12. Synergistic Effect of Low Dose Arsenic and DMBA, DMBA-diol, and DB[a,l]P on
the Spleen Cell TDAR in C57Bl/6J mice. .............................................................................. 33
Figure 13. Synergistic Effect of Low Dose Arsenic and BaP-diol and BPDE on the Spleen Cell
TDAR in C57BL/6J mice. ...................................................................................................... 35

VIII

Figure 14. Arsenic and PAHs Cause Total p53 Up-regulation in WT mice at 8 hour. ................ 37
Figure 15. PAH-induced Immunosuppression was Partly Protected in p53-null mice Spleen
Cells. ....................................................................................................................................... 39
Figure 16. Schematic for Genotoxic Mechanism of Arsenite and PAHs Co-exposure Induced
Immunotoxicity....................................................................................................................... 46

IX

INTRODUCTION

Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BaP) and inorganic
arsenic are toxicologically important compounds that are widely distributed in the environment
(Maier et al., 2002). PAHs are well documented immunotoxicants (Burchiel et al., 2004; Gao et
al., 2008), as are certain inorganic arsenics (Burchiel et al., 2009). However, no studies have
previously evaluated the effect of co-exposure to these agents on the immune system.
Environmental sources of co-exposure to these two compounds include emissions from fossil
fuel combustion, cigarette smoke, and migration from hazardous waste sites. In addition,
occupational exposures to arsenic in nonferrous smelters, pesticide manufacturing, or from
consumption of contaminated drinking water, coupled with tobacco use, represents another
important source for co-exposure to PAHs and arsenic (Maier et al., 2002; Evans et al., 2004).

PAHs Metabolism and Immunotoxicity
Polycyclic aromatic hydrocarbons are a group of chemicals that are formed during the
incomplete burning of coal, oil, gas, wood, garbage, or other organic substances, such as tobacco
and charbroiled meat. There are more than 100 different PAHs, and they usually exist as
complex mixtures in the environment (ATSDR 1996).
The major routes of human exposure to PAHs are consumption of PAHs in foods and
inhalation of the compounds from tobacco smoke, wood smoke, and vehicle exhaust (Collins et
al., 1998; Burchiel et al., 2004). PAHs have been found in coal tar production plants, coking
plants, bitumen and asphalt production plants, coal-gasification sites, smoke houses, aluminum
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production plants, coal tarring facilities, and municipal trash incinerators. For some people, the
primary exposure to PAHs occurs in the workplace. Occupational workers may be exposed to
PAHs by inhaling engine exhaust and by using products that contain PAHs in industries such as
mining, oil refining, metal working, chemical production, transportation, and the electrical
industry. PAHs have also been found in other facilities where petroleum products or coal are
used or where wood, corn, or oil is burned. People living near waste sites containing PAHs may
be exposed through contact with contaminated air, water, and soil.
Structures of PAHs examined in these studies are shown in Figure1. BaP is a prototypical
PAH that has been extensively studied over the past few decades. The metabolism of BaP is
shown in Figure 2. BaP is metabolized by three separate enzymatic pathways (Sims et al., 1974).
CYP1A1 or CYP 1B1 initiate epoxidation of BaP, followed by epoxide hydrolase hydrolyzation,
forming BaP-diol, which is an unstable intermediate metabolite and substrate of CYP. The final
product of BaP metabilism is BPDE, which is not a substrate of mEH because of protection by
steric hindrance of nearby dihydrodiol group. Tumorgenic characteristic of BaP have been
studied by a number of laboratories (Levin et al., 1982; Guengerich et al., 1991). The ultimate
carcinogen of BaP is BPDE (Levin et al., 1982). The Bay region of BPDE is capable of
alkylating DNA and forming bulky adducts by covalently binding to exocyclic amino groups of
purines in DNA to form stable adducts (Guengerich et al., 1991; Song et al., 1998). Thus adduct
formation is important in assessing and predicting carcinogenic potential. Another BaP metabolic
pathway involves formation of radical cations that bind to the N7 or C8 of purines to form
unstable adducts that depurinate to leave apurinic (AP) sites in DNA (Cavalieri et al., 1995). The
third pathway involves the formation of BP-quinones via peroxidases (Shimada and Guengerich
2006, pathway not shown)
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Figure 1. Chemical Structures of Selected PAHs.
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Figure 2. Schematic of Benzo[a]pyrene Metabolic Activation (Figure from “Casarett and
Doull’s Toxicology” seventh edition, 2007).
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DMBA is not naturally occurring in the environment due to its photolysis and
photooxidation properties (Gao et al., 2005). However, it has been studies as a model PAH
extensively (Gonzalez, 2001; Gao et al., 2005). Metabolic activation of DMBA is shown in
Figure 3. The two enzymes responsible for DMBA bioactivation are CYP 1B1 and microsomal
epoxide hydrolase (mEH, EPHX1 gene) (Gonzalez, 2001). The final product of DMBA
metabolism is DMBA-1, 2-epoxide-3, 4-dihydrodiol (DMBA-DE), which is known to be
genotoxic and carcinogenic, as well as highly immunosuppressive (Cavalieri et al., 1995; Gao et
al., 2005).
Dibenzo[a,l]pyrene (DB[a,l]P) is an interesting PAH because it has been discovered
along with other PAHs in particulate matter (PM) air samples sources (Bergvall et al., 2007).
DB[a,l]P has been determined previously as one of the most potent mouse carcinogens
discovered to date (Castro et al., 2008). The metabolic pathway for DB[a,l]P bioactivation is
shown in Figure 4. Previous studies on DB[a,l]P demonstrated that it shares the same CYP and
EH pathways for activation with BaP and DMBA, and it shares the radical cation activation
pathway with BaP and DMBA (Cavalieri et al., 1995).
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Figure 3. Schematic for DMBA metabolism and the formation of the ultimate genotoxic

metabolite of DMBA, DMBA-DE
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Figure 3. Schematic for DMBA metabolism and the formation of the ultimate
genotoxic metabolite of DMBA, DMBA-DE (Gao et al., 2008)
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Figure 4. Schematic of Dibenzo[a,l]pyrene Metabolic Activation Pathways (Figure courtesy
of Dr. David E. Williams, Oregon State University).
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In Vitro and In Vivo Immunotoxicity of PAHs and their Metabolites
The ability of PAHs to suppress immune function has been well documented in human
and murine cell lines, as well as in animal models. BaP and its metabolites have been shown to
induce human B cell apoptosis (Salas et al., 1998), and in human T cells, administration of BaP
can cause decreased T cell proliferation to the mitogens concanavalin A (Con A) and
phytohemagglutinin (PHA) (Davila et al., 1995). Early studies showed that in utero BaP
exposure of pregnant mice lead to severe suppression in the offspring’s ability to produce
antibodies(Urso et al., 1984).
DMBA is a model compound used in studying the immunosuppression of PAHs. DMBA
produces extensive human T-cell suppressions (Mounho et al., 1997), as well as induces pre-B
cell apoptosis and bone marrow toxicity in the mouse (Page et al., 2002). Previous studies in our
lab have shown that DMBA and its metabolites persistently suppress both humoral and cell
mediated immune responses in the mouse model (Burchiel et al., 1990; Burchiel et al., 1992; Gao
et al., 2005). DMBA requires both CYP1B1 metabolism and the presence of p53 for the bone
marrow toxicity to occur in the mouse (Heidal et al., 2002; Page et al., 2003). p53, CYP1B1 and
microsomal epoxide hydrolase (mEH) are both required for spleen cell immunosuppression
produced by DMBA in vivo. p53, CYP1B1, and mEH knockout mice are protected from DMBA
induced immunosuppression (Gao et al., 2005; Gao et al., 2007; Gao et al., 2008).
BaP and DMBA have been shown to suppress ConA and PHA induced human T
lymphocyte proliferation (Mounho et al., 1997). While both BaP and DMBA exposure resulted
in the suppression of the TDAR to SRBC, their metabolites, BaP-7,8-diol and DMBA-3,4-diol
were found to be more immunosuppressive than the parent compounds (Kawabata et al., 1987;
Davila et al., 1996).
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To the best of our knowledge, no research has been done to assess the immunotoxicity of
DB[a,l]P. Here we predicted that it would be a potent immunosuppressant. Our studies indicated
that DB[a,l]P did suppress TDAR to SRBC in murine splenocytes at very low doses, and that it
is even more potent than DMBA.

Arsenic Metabolism and Immunotoxicity
Arsenic is a naturally occurring element in the earth crust. Inorganic arsenicals, arsenite
and arsenate are ubiquitous in the environment. Chronic arsenic toxicity in humans has been
documented in many countries worldwide, particularly in countries of Southeast Asia (Li et al.,
2010). Significant arsenic exposure mostly occurs through drinking arsenic-contaminated water
(ATSDR 2007).
Structures and metabolic pathways of arsenate are shown in Figure 5. Arsenate
metabolism consists of reductions and methylations (Carter et al., 2003). Enzymes that catalyze
the reactions are: arsenate reductase, arsenite/MMAIII metyltransferase, MMAIII reductase, and
DMAV reductase (Aposhian et al., 2004). Previous studies considered methylation a detoxifying
pathway of arsenic, but recently it has been proven that trivalent methylated arsenic metabolites
MMAIII and DMAIII are more toxic than arsenite both in vitro and in vivo (Rossman 2003).
Methylated trivalent metabolites are highly reactive and are potent inhibitors of GSH reductase
and thioredoxin reductase compared with arsenite or pentavalent metabolites (Rossman 2003).
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Figure 5. Known Structures and Metabolic Pathways of Arsenate in Vertebrates (Aposhian
et al., 2004).
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There are several studies on lung carcinogenesis using intratracheal instillation of rats and
hamsters with inorganic arsenic compounds alone or with other carcinogens (Suzuki et al., 2004;
Cohen et al., 2006). However, very high doses of arsenic compounds were required for very little
tumor induction. The ability of various arsenicals to cause tumor promotion was also tested in
rats by examining bladder tumors induced with N-butyl-N-(4-hydroxybutyl) nitrosamine (Cohen
et al., 2007). As a promoter for bladder (strongest response), kidney, liver and thyroid tumor,
arsenite was not active. The most active promoting compound was DMAV, but MMAV and
TMAO were also cancer promoters (Cohen et al., 2006).
Immunotoxic effects of arsenic have been shown in several animal models (Sikorski et al.,
1989; Burns et al., 1993; Burchiel et al., 2009) as well as in humans (Soto-Peña et al., 2006).
B6C3F1 female mice exposed to a single dose of gallium arsenide (GaAs) exhibited an inhibition
of T cell proliferation and macrophage activity, along with a reduction in IgM and IgG
production (Burns et al., 1993). Also, GaAs-treated mice demonstrated a 50% decrease in CD4+
splenic cells after 24 h (Sikorski et al., 1989). A two-week inhalation exposure to arsenic trioxide
in C57Bl/6J mice significantly suppressed the TDAR response by 70% (Burchiel et al., 2009).
Exposure to sodium arsenite in drinking water has been reported to result in a down-regulation of
several cytokines in children living in arsenic contaminated areas in Mexico (Soto-Peña et al.,
2006).
Previous in vitro studies on the genetic toxicology of arsenite have shown that this agent
is not a potent mutagen and does not react directly with DNA (Snow et al., 2005; Klein et al.,
2007). However, at very early times after exposure, As3+ was found to activate NADPH oxidase
activity through a Ras-GTPase mechamism, which creates oxidative damage to cells. Reactive
oxygen spices (ROS) and nitric oxide synthase (NOS) were found to be increased in human
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keratinocytes treated with arsenite (Shi et al., 2004; Qin et al., 2008). A recent study in human
keratinocytes demonstrated that low concentration of sodium arsenite inhibited Poly (ADPribose) Polymerase-1 and interfered with the DNA repair machinery (Ding et al., 2009).

Potential Arsenic-PAH Interactions
While arsenic alone is not a potent carcinogen, recent studies show that it plays a role in
PAH and UVA induced carcinogenesis (Maier et al., 2002; Evans et al., 2004). Recent studies
showed that arsenite co-treatment enhanced the formation of stable BaP–DNA adducts and this
increase in genotoxicity was found to be cytochrome p450 1A1 (CYP1A1)-dependent. Evidence
also showed that glutathione depletion enhanced the potentiating effect of arsenite on formation
of adducts.
Based on the fact that immunosuppression has been demonstrated by PAHs and arsenic
separately, we were interested in exploring the immunotoxic effects by combination of these two
agents. Both arsenic and PAHs exposure have been shown to produce genotoxicity and oxidative
stress. We believe that genotoxicity may be the major pathway for both arsenic and PAH induced
immunosuppression. Therefore, the present studies were designed to characterize the
immunosuppressive properties of selected PAHs and arsenic and to determine whether these two
classes of chemicals produce synergistic or additive immunosuppression. The second goal of this
study was to determine whether the immunosuppression by arsenic and PAHs is p53-dependent.
Finding that PAH and arsenic alter p53 alone or in combination would provide initial evidence
for a genotoxic mechanism of action for these agents.
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HYPOTHESIS AND SPECIFIC AIMS

Hypothesis
The hypothesis tested in this study is that arsenic and PAHs co-exposures potentiate
immunosuppression in C57BL/6J mouse splenocytes. The current study also hypothesized that
p53 is associated with the immunosuppression produced by arsenic and PAHs.

Specific Aim 1
Develop an in vitro model to examine PAHs and arsenic induced
immunosuppression given alone or in combination.

Specific Aim 1a
Determine and establish dose responses for TDAR immunosuppression produced by
sodium arsenite, sodium arsenate, BaP, DMBA, DB[a,l]P, and selective PAH metabolites. This
was achieved by in vitro treatment of wild type mouse spleen cells using various doses of PAHs
(listed above), arsenite and arsenate, followed by examination of the TDAR assay to test
immunosuppression.

Specific Aim 1b
Determine if co-exposure to arsenic and PAHs potentiates the immunosuppression
compared to PAH alone. This was done by combining the treatments of arsenic and PAHs in
wild type mice spleen cells and testing the immunosuppression using TDAR.
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Specific Aim 2
Study the mechanism of immunosuppression produced by Arsenic and PAHs alone
or in combination in mice splenocytes.

Specific Aim 2a
Determine if the arsenic and PAH immunosuppression is p53 dependent. This was done
by combining the in vitro treatments of arsenic and PAHs in p53 knockout mice spleen cells and
testing the immunosuppression by TDAR to see if p53 null mice are protected from arsenicPAHs induced immunosuppression.

Specific Aim 2b
Study p53 protein regulation in response to arsenic and PAH treatments. This was done
by examining p53 protein level in mouse spleen cells treated with arsenic and/or PAHs using
Western blot analysis as described in the Material and Methods.
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MATERIALS AND METHODS

Chemicals and reagents.
Sodium arsenite, sodium arsenate, benzo[a]pyrene, 7,12-dimethylbenz[a]thracene
(DMBA) and dibenzo[a,l]yrene (DB [a,l]P) were purchased from Sigma-Aldrich (St. Louis, MO).
Benzo[a]pyrene-trans-7,8dihydrodiol, Benzo[a]pyrene-trans-7,8dihydrodiol-9,10-epoxide and
7,12-Dimethylbenz[a]-anthracene-trans-3,4-dihydrodiol were obtained from National Cancer
Institute Chemical Respository (Kansas City, MO). Sodium arsenitewas dissolved in culture
grade water, PAHs were dissolved in culture grade anhydrous dimethylsulfoxide (DMSO; Sigma,
St. Louis, MO). Both water and DMSO served as the solvent control. The final concentrations of
water and DMSO in all cell cultures were 0.1%. This concentration was determined to be
without measurable effect on cellular response. Cell culture materials were from Sigma-Aldrich
and Invitrogen (Grand Island, NY).

Animals.
Male wild-type C57BL/6J mice (6-8 weeks old) were purchased from Jackson
Laboratories (Bar Harbor, ME). p53-null mice breeders were purchased from The Jackson
Laboratory. These knockout mice were bred in our Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)-accredited animal facility under an
Institutional Animal Care and Use Committee-approved protocol. All knockout mice were
genotyped using a polymerase chain reaction genotyping method with DNA isolated from tail
snips (Jacks et al., 1994; Miyata et al., 1999). No animals bearing tumors were used in these
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studies. In all of the experiments, mice were euthanized by CO2, followed by spleen cell isolation,
described as below. All mice were used at the age of 10-14 weeks old. Mice spleen weights were
recorded at the time of euthanasia.

Spleen cell preparation.
Single cell suspensions were prepared and combined from three individual mice per
treatment group. Spleen cells were harvested as described previously (Gao at al., 2005). In brief,
spleens cells were isolated in RPMI 1640 complete medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 µg/ml streptomycin and 100 Units/ml penicillin, and centrifuged
at 280x g for 10 min. Cell pellets were resuspended and maintained in RPMI 1640 complete
medium on ice. Viable spleen cell counts were obtained by the trypan blue (Sigma Chemical Co.,
St. Louis, MO) exclusion method using a hemacytometer.

In vitro treatment and plaque-forming cell assay.
Mouse spleen cells collected sterilely (4 x 106 cells/ml, 0.5 ml) were treated with arsenic
and/or PAHs and cultured for four days with 0.5 ml of twice washed 1% sheep red blood cells
(SRBC) (Colorado Serum, Denver, CO) in 48-well, flat-bottomed plates (Corning Glass,
Corning, NY) with PFC media [RPMI 1640 medium with 10% heat inactive fetal bovine serum
(Atlanta Biologicals, Lawrenceville, GA), 50 µM 2-mercaptoethenol (GIBCO, Grand Island,
NY), 1 mM sodium pyruvate (GIBCO, Grand Island, NY) and 50 µg/ml gentamycin (GIBCO,
Grand Island, NY)]. The plates were placed in a humidified, 37°C, 5% CO2 incubator. PFC
media without SRBC were added into the spleen cells as control. Quadruplicate cultures were
run for each treatment with SRBC. Meanwhile, a control plate for checking cell viability is also
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set up. Four days later, a glass slide modification of Jerne and Nordin (1963) PFC assay was
performed. Briefly, the immunized spleen cells were collected from individual cultures into glass
tubes, and washed twice with PFC media. Then 50 µl 50% SRBC were then added to each glass
tube. These tubes were placed in a 43°C constant temperature water bath with 400 µl 0.8%
Seaplaque agarose (Intermountain Scientific, Kaysville, UT). SRBC were added to the tubes and
one slide was used for each culture (quadruplicate) to determine the PFC response. The mixture
of spleen cells and SRBC was poured onto 3x1x1 mm, 0.15% Seaplaque agarose precoated
microscope slide and allowed to cool. The slides were inverted on costom-made slide trays. The
slides were incubated for 1.5 h at 37°C in a humidified without CO2 incubator. Guinea pig
complement (Colorado Serum, Denver, CO) in Dulbecco’s phosphate buffered saline (DPBS)
with calcium and magnesium (1:20) was used to flood the slides on each tray. Following
additional 2 h incubation at 37°C, the numbers of anti-SRBC plaque-forming cells (PFC) per
culture were identified by dissecting microscope. The data are presented as the number of
PFC/culture (2 x 106cells per culture on day 0).

In vitro treatment and whole cell lysate preparation.
Mouse spleen cells were collected sterilely as described above (6 x 106 cells/ml, 1ml) in
PFC media [PMI 1640 medium with 10% heat inactive fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA), 2mM L-glutamine (GIBCO, Grand Island, NY), 100 U/ml penicillin with
100 µg streptomycin sulfate (Lonza, Walkersville, MD) and 50 µg/ml gentamycin (GIBCO,
Grand Island, NY)] in 48-well, flat-bottomed plates. Cells were treated with arsenic and/or PAHs
and cultured for 4 h, 8h and 18h in a humidified, 37°C, 5% CO2 incubator. To prepare the whole
lysate, spleen cells from each treatment were collected in a 15 ml centrifuge tube, centrifuged at
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280 x g for 10 min at 4°C. The supernatants were discarded, and the pellets were resuspended in
2 ml ammonium chloride lysine solution (10 X; 1.5 M ammonium chloride, 100 mM sodium
bicarbonate, 10mM disodium EDTA, pH 7.4). Samples were held at room temperature for 10
min, followed by washing twice with DPBS. The pellets were resuspended in 200 µl RIPA
buffer (50mM Tris, 150mM sodium chloride, 0.1% SDS, 0.5% sodium deoxycholate, 1% triton
X100, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and Roche Complete
Protease Inhibitor Tablet, pH 7.4) and transferred to 1.5 ml micrfocentrifuge tubes. Suspensions
were held on ice for 10 min, sonicated on ice for 10 sec, centrifuged at 18,000 x g for 10 min at
4°C. The supernatant were collected in a 0.65 ml microcentrifuge tube. Total protein
concentrations were determined using Protein Assay reagent (Bio-Rad Laboratories, Hercules,
CA)

Western blot analysis.
Total p53 and ß-actin expression were analyzed as previously described (Gao et al.,
2005). Briefly, 100 µg of whole cell lysate was heated at 95°C for 5 min with 6X sample buffer
(0.35M Tris, pH6.8, 30% Glycerol, 10% SDS, 0.6M dithiothreitol, 0.012% bromphenol blue).
Samples were separated by SDS polyacrylamide gel electrophoresis using a 10% resolving gel
with a 5% stacking gel and a mini-PROTEIN 3 cell system (Bio-Rad Laboratories). After 1 h
electrophoresis at 180 Volts, protein was transferred to nitrocellulose membranes (0.45 µm; BioRad Laboratories) for 1 h using a constant 300 milliamps current. Nonspecific binding was
blocked by incubating membranes in 5% (w/v) Nonfat Dry Milk (Bio-Rad Laboratories) in Trisbuffered saline containing Tween 20 [BS/T; 50 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% (v/v)
Tween 20] at room temperature for 1 h. Incubation was followed by three 5 min TBS/T washes;
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membranes were then incubated with a p53 1C12 antibody (1:1000; Cell Signaling Technology
Inc., Danvers, MA) in 5% bovine albumin BSA (Sigma-Aldrich) in TBS/T at 4°C overnight.
After washing with TBS/T, membranes were incubated with a horseradish peroxidase (HRP)conjugated anti-mouse IgG secondary antibody (1:2000; Cell Signaling Technology Inc.) for 1 h
at room temperature in 5% BSA in TBS/T. The protein bands were detected using a
SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, IL) and
visualized on a Kodak Image Station 4000 mm (Eastman Kodak, Rochester, NY). The protein
molecular weight was determined by comparison with Precision Plus Protein Western C
standards (Bio-Rad Laboratories). After detection of p53 protein, the membranes were stripped
using Gentle ReView Buffer (Amresco Inc., Solon, Ohio) in a 37°C water bath for 30 min and
were then probed with ß-actin antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA).

Statistical analysis.
All of the data reported in this paper were analyzed by SigmaStat software (Jandel
Scientific, San Rafael, CA). The statistical differences were determined by one-way analysis of
variance (ANOVA). A p-value of <0.05 will be considered significant. Data is reported as the
average + SEM for replicate cultures (as indicated) which measures the inter-culture variability
of treatments rather than the inter-animal variation in response.
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RESULTS

SPECIFIC AIM 1

DMBA and DMBA-diol Suppress the Spleen Cell TDAR in C57BL/6J mice.
Our laboratory has previously shown that TDAR is a very sensitive method to examine
immunosuppression that xenobiotics may produce in vitro and in vivo (Burchiel et al., 1990;
Burchiel et al., 2009). To characterize the spleen cell humoral immune response following
DMBA or DMBA-diol treatments, the TDAR response to SRBCs was examined in vitro using
PFC assay (Figure 6). Both DMBA and DMBA-diol produced concentration-dependent
suppression in the TDAR response in C57Bl/6J mice spleen cells. At the lowest concentration of
DMBA tested (0.1 μM) a 30% suppression in TDAR compared to DMSO vehicle control was
detected, whereas DMBA-diol produced nearly the same level of suppression at a concentration
of 0.001 μM. These results indicate that DMBA-diol is 30-100 times more potent than the parent
compound in producing immunosuppression in our system.
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Figure 6. DMBA and DMBA-diol Suppress the Spleen Cell TDAR in C57BL/6J mice.
Spleen cells were immunized in vitro at the same time of treatment with DMSO, DMBA, or
DMBA-diol. The number of antibody producing spleen cells was determined by TDAR PFC
assay as described in the Materials and Methods. No cytotoxicity compared to control was
observed in these cultures. Data are for a pool of three mice spleens that were assayed in
quadruplicate culture. Data are shown as mean + S.E.M. * indicates statistically significant
differences from 0.1% DMSO control (p< 0.05).
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Immunosuppressive Effect of DB[a,l]P on the Spleen Cell TDAR in C57Bl/6J mice.
DB[a,l]P has been shown to share several chemical properties and has a reactive
biological structure similar to DMBA (Melendez-Colon et al., 1999). The immunotoxicity of
DB[a,l]P has not been previously reported. We found that DB[a,l]P produced a concentrationdependent suppression of the TDAR response. In fact, DB[a,l]P was even more potent than
DMBA (Figure 7). Following DB[a,l]P exposure of murine spleen cells in culture for four days,
0.001 μM DB[a,l]P produced 40% suppression of the TDAR compared to the 0.1% DMSO
control cultures. These results suggest that DB[a,l]P may be up to 100 times more potent than
DMBA in producing immunosuppression.
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Figure 7. Immunosuppressive Effect of DB[a,l]P on the Spleen Cell TDAR in C57Bl/6J
mice.
Spleen cells were immunized in vitro with SRBC, and treated with DMSO or DB[a,l]P. The
number of antibody producing spleen cells was determined by a TDAR PFC assay as described
in the Materials and Methods. No cytotoxicity compared to control was observed in these
cultures. Data for a pool of spleen cells from three mice cultured in quadruplicate are shown as
mean + S.E.M. Statistically significant differences compared with 0.1% DMSO are indicated (*,
p< 0.05).
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Immunosuppressive Effect of BaP, BaP-diol and BPDE on the Spleen Cell TDAR in
C57BL/6J mice.
Because BaP is an important environmental PAH that is bioactivated by cells to form
BaP-diol and BPDE, we compared the concentration-dependent effects of these three agents
(Figure 8). These PAHs exhibited different potencies for suppression of the TDAR. At a
concentration of 1 μM, BaP produced about 50% suppression of the TDAR, whereas BaP-diol
was 10-fold more immunosuppressive than BaP, and BPDE was 100 times more suppressive
than BaP. These observations agree with our current understanding that BaP needs to be
metabolized by CYPs (1A1 and 1B1) and microsomal epoxide hydrolase (EPHX1) to exert its
immunotoxicity.
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Figure 8. Immunosuppressive Effect of BaP, BaP-diol and BPDE on the Spleen Cell TDAR
in C57BL/6J mice.
Spleen cells were immunized in vitro with SRBC, and treated with DMSO, BaP, BaP-diol, or
BPDE. The number of antibody producing spleen cells was determined by a modified Jerne and
Nordin PFC assay as described in the Materials and Methods. No cytotoxicity was observed in
these cultures compared to control culture. Data for a pool of three mouse spleens, assayed in
quadruplicate, are shown as mean + S.E.M. Statistically significant differences compared with
0.1% DMSO are indicated (*, p< 0.05).
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Immunosuppressive Effects of NaAsO2 and Na2HAsO4 on the Spleen Cell TDAR in C57Bl/6J
mice.
Sodium arsenite and sodium arsenate immunotoxicity in C57BL/6J mice spleen cells
were measured using the TDAR and PFC assay (Figure 9). They both had immunosuppressive
effects in a dose-dependent manner. Sodium arsenite (As3+) was found to suppress the TDAR at
concentrations as low as 0.5 μM. Sodium arsenite was found to be at least 10-fold more
suppressive to the TDAR than sodium arsenate (As5+).
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Figure 9. Immunosuppressive Effects of As3+ and As5+ on the Spleen Cell TDAR in
C57Bl/6J mice.
Spleen cells were immunized in vitro with SRBC and treated with H2O (arsenic vehicle) or As3+,
As5+. The number of antibody producing spleen cells was determined using a modified Jerne and
Nordin PFC assay as described in the Materials and Methods. No cytotoxicity was observed in
these cultures compared to control. Data for a pool of three mouse spleens those were assayed in
quadruplicate, shown as mean + S.E.M. Statistically significant differences compared with 0.1%
H2O are indicated (*, p< 0.05).
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Immunosuppressive Effect of Combining As3+ and DMBA-diol on Splenocytes TDAR from
C57Bl/6J mice.
In order to examine the effect of co-exposure to arsenite and DMBA-diol, 0.5 μM and 5
μM doses of sodium arsenite were chosen to combine with DMBA-diol at 0.001 μM, 0.01 μM
and 0.1 μM respectively. Spleen cells were treated and immunized with SRBC at the same time.
The TADR PFC assay was used to measure immunosuppression. As shown in Figure 10,
DMBA-diol produced a dose-dependent immunosuppression of the TDAR PFC response. The
0.5 µM dose of sodium arsenite in the cell cultures greatly potentiated immunosuppression
produced by DMBA-diol by itself at 0.001 μM.
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Figure 10. Immunosuppressive Effect of Co-exposure to As3+ and DMBA-diol on C57Bl/6J
mice Splenocytes TDAR.
Spleen cells were immunized in vitro with SRBC and treated with DMSO or As3+ and/or
DMBA-diol. Immunotoxicity was determined by TDAR PFC assay as described in the Materials
and Methods. No cytotoxicity compared to control was observed in these cultures compared to
control culture. Data from a pool of three mouse spleens were assayed in quadruplicate and are
shown as mean + S.E.M. Percentage indicates suppression relative to control (H2O for arsenic,
DMSO for PAHs). * indicates a statistically significant difference compared with vehicle control
(p< 0.05). #indicates a statistically significant effect of arsenite when added to PAHs compared to
the PAH alone (p < 0.05). Numbers in parenthesis indicate % suppression compared to vehicle
control. Data are representative of two experiments.
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Immunosuppressive Effect of Co-Exposure to As3+ and DB[a,l]P on C57Bl/6J mice
Splenocytes TDAR.
In order to examine the co-effect of arsenite and DB[a,l]P, sodium arsenite at doses of
0.5 μM and 5 μM was chosen to combine with series doses of DB[a,l]P, ranging from 0.001 μM
to 0.1 μM. Spleen cells were treated and immunized with SRBC at the same time. The TADR
PFC assay was used to measure immunosuppression. As shown in Figure 11, DB[a,l]P produced
a dose-dependent immunosuppression of the TDAR PFC response. Adding 0.5 µM of sodium
arsenite to the cell cultures greatly increased immunosuppression compared to DB[a,l]P by itself
(0.001 μM).
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Figure 11. Immunosuppressive Effect of Combining As3+ and DB[a,l]P on C57Bl/6J mice
Splenocytes TDAR.
Spleen cells were immunized in vitro with SRBC and treated with DMSO or As3+ and/or
DB[a,l]P. Immunotoxicity was determined by TDAR PFC assay as described in the Materials
and Methods. No cytotoxicity was observed in these cultures compared to control. Data from a
pool of three mouse were assayed in quadruplicate and are shown as mean + S.E.M. * indicates
a statistically significant difference compared with vehicle control (p< 0.05). #indicates a
statistically significant effect of arsenite when added to PAHs compared to the PAH alone (p <
0.05). Numbers in parenthesis indicate % suppression compared to vehicle control. Data are
representative of two experiments.
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Synergistic Effect of Low Dose Arsenic and DMBA, DMBA-diol, and DB[a,l]P on the Spleen
Cell TDAR in C57Bl/6J mice.
The immunotoxicity of PAH and arsenic co-exposures were evaluated by treating
C57BL/6J mice spleen cells with 0.5 μM sodium arsenite with or without 0.1 μM DMBA, 0.001
μM DMBA-diol, and 0.001 μM DB[a,l]P (Figure 12). These doses were chosen based upon
results obtained in previous experiments that established a no-effect or low-effect level of
exposure for these agents. As shown in Figure 11, 0.1 μM DMBA, 0.001 μM DMBA-diol, and
0.001 μM DB[a,l]P did not produce significant suppression by themselves; however, by adding
0.5 µM of sodium arsenite to the cell cultures, immunosuppression by each of these agents was
greatly increased relative to the modest effects of arsenite alone. Because the individual agents at
the concentrations employed did not produce significant immunosuppression on their own, these
findings demonstrate the synergy between co-treatment of As3+ and DMBA, DB[a,l]P in
suppression of the TDAR, a result that was also seen with BaP and its metabolites (below).
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Figure 12. Synergistic Effect of Low Dose Arsenic and DMBA, DMBA-diol, and DB[a,l]P
on the Spleen Cell TDAR in C57Bl/6J mice.
Spleen cells were immunized in vitro and treated with DMSO or H2O, DMBA, DMBA-diol or
DB[a,l]P with or without As3+. Immunotoxicity was determined by TDAR PFC assay as
described in Materials and Methods. No cytotoxicity was observed in these cultures compared to
control. Data from a pool of three mouse spleens that were assayed in quadruplicate are shown as
mean + S.E.M. * indicates a statistically significant difference compared with vehicle control
(p< 0.05). #indicates a statistically significant effect of arsenite when added to PAHs compared to
the PAH alone (p < 0.05). Data are representative of two experiments.
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Synergistic Effect of Low Dose Arsenic and BaP, BaP-diol and BPDE on the Spleen Cell
TDAR in C57BL/6J mice.
To evaluate effect of co-exposure of BaP and arsenic, we chose non-cytotoxic doses of
BaP, BP-diol, and BPDE to combine with sodium arsenite to determine effects on the TDAR.
We found that spleen cell cultures co-treated with low doses of sodium arsenite and BaP-diol as
well as those treated with sodium arsenite and BPDE demonstrated synergistic
immunosuppressive effects (Figure 13). 0.01 μM BaP-diol and 0.001 μM BPDE did not produce
significantly suppression by themselves; however, when co-treated with 0.5 µM of sodium
arsenite to the culture media, we found significant immunosuppression. Combined with the
results shown in Figure 11, these results demonstrate a synergistic interaction between PAHs and
As3+.
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Figure 13. Synergistic Effect of Low Dose Arsenic and BaP-diol and BPDE on the Spleen
Cell TDAR in C57BL/6J mice.
Spleen cells were immunized in vitro with SRBC and treated with DMSO, As3+, and/or BaP,
BaP-diol and BPDE at the same time. The number of antibody producing spleen cells was
determined by a modified Jerne and Nordin PFC assay as described in the Materials and
Methods. Data from a pool of three mouse spleens were assayed in quadruplicate, and are shown
as mean + S.E.M. No cytotoxicity was observed in these cultures compared to control. *
indicates a statistically significant difference compared with vehicle control (p< 0.05). # indicates
a statistically significant effect of arsenite when added to PAHs compared to the PAH alone (p <
0.05). Data are representative of two experiments.
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SPECIFIC AIM 2

As3+ and PAHs alone and in combination cause p53 up-regulation in WT mice at 8 hrs.
Previous studies in our laboratory have shown that DMBA triggers a significant p53 upregulation in WT mice in a dose-dependent manner (Gao et al., 2008). In the current study, as
shown in Figure 14, WT mice spleen cells were treated with sodium arsenite and/or DB[a,l]P for
4h, 8h and 18h. Western blot analysis was performed to examine total p53 protein levels. At 4
hour, the p53 level was not significantly increased by any of the treatments. The highest increase
of p53 protein expression was observed following 8 hours of exposure. At this time point, 5 µM
sodium arsenite treatment resulted in a 3-fold increase of p53 protein levels; 0.01 µM DB[a,l]P
induces 1.5 fold increase of p53 protein compared to DMSO control. Combining 5 µM sodium
arsenite and 0.01 µM DB[a,l]P up-regulated p53 protein by about 5-fold at 8 hour time point.
Upon 18 hour treatment, p53 total protein level was decreased compare to 8 hour treatment.
Taken together, Western blot results showed that p53 protein was up-regulated in a dose- and
time-dependent manner following As3+ and PAH treatments of murine spleen cells.
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•
•
•
•
•
•

L1: 0.1% H2O
L2: 0.1% DMSO
L3: 0.5 µM As+3
L4: 5 µM As +3
L5: 0.001 µM DB[a,l]P
L6: 0.01 µM DB[a,l]P

•
•
•
•
•
•

L7: 0.001 µM DMBA-diol
L8: 0.01µM DMBA-diol
L9: 0.1% H2O
L10: 0.1% DMSO
L11: 5 µM As +3 + 0.01 µM DB[a,l]P
L12: 5 µM As +3 + 0.01 µM DMBA-diol

Figure 14. Arsenic and PAHs Cause Total p53 Up-regulation in WT mice at 8 hour.
Male WT mice spleen cells were collected as described in Material and Method, treated with
DMSO, As3+ and/or DB[a,l]P for 4 h, 8 h and 18h. Following treatment, cells were lysed, and
total protein was resolved by SDS-PAGE. Total p53 activity was determined by immunoblot
with p53 1C12 antibody. The normalized protein levels were indicated as ratio at the bottom of
each blot by densitometry analysis using ß-actin as loading control.
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PAH-induced Immunosuppression was Partly Protected in p53-null Mice Spleen Cells.
Previous studies in our laboratory showed that p53 knockout mice were protected from
DMBA-induced immunotoxicity measured using an ex vivo spleen cell TDAR PFC (Gao et al.,
2007). To determine if p53 is required for the arsenic/PAHs immunotoxicity in the current in
vitro system, we immunized p53-null mice with sheep red blood cell, treated with the
combination of 0.5 µM of sodium arsenite and low dose of DMBA, DMBA-diol and DB[a,l]P.
TDAR PFC assay was conducted to evaluate IgM antibody production as shown in Figure 15. In
Table 1, we calculated the actual percentage of the TDAR suppression using a low dose (.001
μM) of DMBA-diol + As3+ (.5 μM) and a low dose (.001 μM) of DB[a,l]P + As3+ (.5 μM), and
compared the data from p53-null mice to WT mice. We found that spleen cells from p53 null
mice exposed to DMBA-diol + As3+ were significantly protected from immunosuppression as
compared to the WT mice. As shown, we found that p53-null mice were protected from the As3+
+ DMBA-diol (96% suppression in WT mice and only 46% suppression in p53 null mice), as
well as the As3+ + DB[a,l]P immunosuppression (75% suppression in the WT mice and only 21%
suppression in the p53 null mice). Interestingly, immunotoxicity produced by the single low
dose exposures to DMBA-diol, As3+, or DB[a’l]P were less protected in the p53 null mice.
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Figure 15. PAH-induced Immunosuppression was Partly Protected in p53-null mice Spleen
Cells.
Spleen cells from three p53-null mice were pooled, immunized in vitro and treated with DMSO,
As3+, and/or DMBA, DMBA-diol and DB[a,l]P. The number of antibody producing spleen cells
was determined by a TDAR PFC assay as described in Materials and Methods. Data from a pool
of three mice spleens were assayed in quadruplicate. Data are shown as mean + S.E.M. No
cytotoxicity was observed in these cultures compared to control. * indicates a statistically
significant difference compared with 0.1% H2O+ 0.1% DMSO (p< 0.05). Data are representative
of two experiments.
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Table 1. Percent Suppressions of TDAR by PAHs + As3+ in WT vs. p53-null mice.
Numbers are representatives of the TDAR suppression percentage compared to vehicle controls.
Data for WT for the treatments 0.001 μM DMBA-diol, 0.5 μM As3+ and DMBA-diol + As3+ in
WT are from Figure 10, Data for WT for the treatments 0.001 μM DB[a,l]P, 0.5 μM As3+ and
DB[a,l]P + As3+ in WT are from Figure 11. p53-null data are from Figure 15.

0.001 μM
DMBAdiol
C57BL/6J
WT
p53-null

0.5 μM
As3+

DMBAdiol + As3+

0.001 μM
DB[a,l]P

0.5 μM
As3+

DB[a,l]P +
As3+

36%

36%

96%

26%

24%

75%

23%

23%

46%

30%

23%

21%
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DISCUSSION
Environmental exposure of humans to PAHs and arsenic is a concern from a global
health perspective. EPA has classified both classes of chemical agents as important carcinogenic
and immunotoxic chemicals. The present studies were designed to characterize the
immunosuppression of PAHs and arsenic in spleen cells from C57BL/6J mice using a Tdependent antibody response, and to study possible mechanisms of their interaction. The murine
immune system was proved previously to be an excellent predictor of human
immunosuppression produced by environmental chemicals (Vos and Van, 1998).
PAH immunosuppression has been studied for decades in animal models (Schnizlein et
al., 1987; Burchiel et al., 1990; Gao et al., 2005) and in cell lines (Davila et al., 1996). BaP and
DMBA are prototypical PAHs that are well characterized immunosuppressants. In the current
study, we investigated the TDAR in vitro in C57BL/6J mice spleen cells exposed to BaP, DMBA
and their metabolites, and compared their different potencies. The TDAR is a sensitive and
commonly utilized assay for assessment of immunosuppression (White et al., 2010). A dosedependent decrease in TDAR was observed in the presence of the T-dependent antigen, sheep
red blood cells, for each investigated PAH. Metabolites exhibited much higher potency than
parent compounds. This is likely to be explained by previous studies which shows that DMBA
bioactivation requires CYP and mEH to be genotoxic and immunosuppressive (Gao et al., 2005;
Gao et al., 2007; Gao et al., 2008). Uno et al. have also previously shown that CYP1B1 is
required for BaP metabolism and immunotoxicity (Uno et al., 2006).
DB[a,l]P is an important environmental PAH, which has been identified along with other
PAHs, in ambient particulate matter (PM) samples and other sources (Bergvall et al., 2007).
DB[a,l]P has been previously studied as one of most potent carcinogens evaluated in the mouse
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model (Castro et al., 2008). Treatment of pregnant mice with DB[a,l]P resulted in the formation
of a highly progressive T-cell lymphoma in their offspring. Mice that survived to 10 months of
age developed lung tumors. Previous studies indicated that DB[a,l]P shared some chemical and
biological characteristics similar to DMBA (Melendez-Colon et al., 1999). DB[a,l]P is
bioactivated by CYP1B1and leads to the formation of metabolite that interact with DNA,
forming an AP site and causing DNA damage (Castro et al., 2008; Busters et al., 2002). To our
knowledge, no previous study has examined the immunotoxicity of DB[a,l]P. In the present
studies, we hypothesized that DB[a,l]P would be a potent immunosuppressant of the TDAR
based upon its known genotoxicity. In agreement with this hypothesis, we found that DB[a,l]P
produced a dose-dependent immunosuppression of the TDAR in the in vitro murine spleen cell
system. In addition, we found that DB[a,l]P is about 10-fold more potent than DMBA. The
lowest concentration of DB[a,l]P that produced a statistically suppression of TDAR is 0.001 µM.
Thus, our studies showed that DB[a,l]P is a potent immunosuppressant.
Turning our attention to the other environmental chemical examined in these studies, we
know that arsenic is a widely distributed contaminant in the environment. Immune suppression
by arsenic has been observed in previous studies in vitro and in vivo in animal models and in
humans living in arsenic contaminated areas. Early studies in the mouse model showed that a
200 mg/kg intratracheal exposure of gallium arsenide impairs both humoral and cellular immune
responses (Sikorski et al., 1989). Recent studies in our laboratory showed that 50 µg/m3 and 1
mg/m3 inhalation exposures of arsenic trioxide produced extremely suppression of the TDAR to
sheep red blood cells (Burchiel et al., 2009). This indicates potential risk of lung diseases that
might result from arsenic inhalation exposure. A study that investigated immune effects of
arsenic in drinking water in an exposed population of children living in central Mexico showed
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that T cell activation was suppressed (Soto-Peña et al., 2006). A more recent study in individuals
living in a arsenic contaminated area in India, found a significant decrease in cytokines
produced by T cells and a marked dose-dependent suppression of Concanavalin A (Con A)
induced proliferation responses in exposed individuals (Biswas et al., 2008).
In the present study, we characterized TDAR immunosuppression in mouse splenocytes
exposed to sodium arsenite (As3+) or sodium arsenate (As5+). These are two inorganic forms of
arsenic found in the environment. We found arsenite was 10-fold more potent in suppressing
TDAR than arsenate in our system. This is consistent with previous studies, showing that
pentavalent arsenic is more potent than trivalent arsenic in suppressing the function of pulmonary
alveolar macrophages (Lantz et al., 1994). In addition, previous studies have shown that As3+
induces more ROS production and DNA damage than As5+ (Ding et al., 2009). These might be
important mechanisms to explain the observation in our study that As3+ was more potent in
inducing immunosuppression than As5+ in our system.
Our studies also investigated the immunosuppressive effects produced of arsenic and
PAH co-exposure in normal C57/BL6J mouse splenocytes. Our results indicated that at low
doses, As3+ potentiated the immunosuppression produced by PAHs, specifically DMBA,
DMBA-diol, DB[a,l]P, BaP-diol and BPDE. A concentration of 0.5µM of As3+ by itself did not
cause significant immune suppression, whereas combined treatments of low doses arsenic and
PAHs significantly potentiated immunosuppression. These studies indicate to us that low levels
of arsenic and PAH co-exposure may have synergistic immunosuppressive effects. This is the
first report that describes the co-effect of arsenic and PAHs in immunosuppression. The 0.5 µM
level (65 ppb) of arsenic used in this study to show synergism with PAHs was only modestly
higher than the current EPA limit for arsenic in drinking water in the United States 10 ppb. Many
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world populations are exposed to levels of arsenic in the range of 100-1000 ppb. Therefore these
studies suggest that further environmental arsenic toxicity assessments should be performed and
evaluated in human populations.
Regarding potential mechanisms whereby PAHs may interact with As3+ to produce
immunosuppression, we hypothesized that there is a relationship between the amount of
genotoxicity produced by xenobiotics and their resultant immunotoxicity. Luster et al have
shown that many genotoxic agents are immunosuppressant (Luster et al., 1992). Recent studies
have also shown that arsenic greatly potentiates BaP genotoxicity (Maier et al., 2002). DNA
adducts levels in mouse skin and lung produced by BaP were found to be increased 8-fold by
arsenic (Evans et al., 2004). These studies suggest that arsenic and BaP interacted in vivo and in
vitro. While the mechanism of arsenic and PAH interaction remains unexplained, these studies
provide important rationale for present study on low doses of arsenic and PAH synergistic
immunosuppression of the TDAR. We believe that genotoxicity is the major pathway for arsenic
and PAH induced immunotoxicity. As shown in Figure 16, we hypothesize that PAH metabolites
that are formed via P450 and epoxide hydrolase activation form bulky adducts that are genotoxic
leading to DNA strand breaks, mutations and cancer. These adducts are sensed by ATM/ATR,
leading to p53 activation and immunosuppression. This conclusion is based upon a recent series
of studies in our laboratory, showing that DMBA, in the presence of mEH and CYP1B1
produces immunotoxicity via a genotoxic mechanism (Gao et al 2008). Gao et al also found that
p53 was increased by DMBA via ATM/ATR activation, and presumably cell cycle inhibition
which is associated with immunosuppression.
We believe that As3+ may interfere with DNA repair by replacing Zn in Zn-finger
proteins leading to inhibition of protein activity. A current hypothesis under evaluation in our
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laboratories (collaboration with Liu and Hudson labs) is that one such Zn-fingered protein that
may be inhibited by As3+ is Poly (ADP-ribose) Polymerase-1 (PARP). The role of PARP in the
repair of DNA bulky adducts such as PAHs has not been well-established. However, a recent
study demonstrated that a low concentration of sodium arsenite inhibited and interfered with
DNA repair machinery in human keratinocytes (Qin et al., 2008; Ding et al., 2009). Thus, we
believe that by interfering with the DNA repair system, arsenic might potentiate the
immunotoxicity of PAHs by increasing the amount of unrepaired adducts leading to enhanced
genotoxicity (shown in Figure 16). We also cannot rule out a role for oxidative stress-associated
pathways that may play a role in the formation oxidative adducts, such as 8-OHdG, that mediate
non-genotoxic signaling pathways.
In support of a genotoxic mechanisms of action for the combined effects of PAHs and
As3+, we found that p53 total protein levels were increased in mouse spleen cells treated with
As3+ and PAHs alone or in combination. The fact that p53 was increased for both As3+ and PAHs
provides initial evidence for this hypothesis. Co-treatment of spleen cells with As3+ and PAH
induced a significantly greater up-regulation of p53 compared to As3+ or PAH given alone.
Previous studies have shown that p53 is induced following arsenic exposure. Arsenic trioxide
was shown to induce p53 in a dose-dependent manner in human leukemia cell lines (Yedjou et
al., 2009). Chronic exposure of low level arsenite in human keratinocytes exhibited poly(ADPribosyl)ation of p53 which interferes with p53 activation (Komissarova et al., 2010). Thus the
findings reported in the present studies are consistent with literature reports on the induction of
p53 by As3+.
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Figure 16. Schematic for Genotoxic Mechanisms of Arsenite and PAHs Co-exposure
Induced Immunotoxicity.
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In further support of our genotoxicity and p53 hypothesis for PAH and As3+ interactions,
we found that p53-null mice were mostly protected from immunosuppression produced by
arsenic and PAH co-treatment. This result is consistent with previous studies showing that p53 is
required for DMBA-immunotoxicity (Gao et al., 2008). Further in vivo studies are needed in
p53-nulll mice. However, these initial results are consistent with our current thinking that p53 is
a key regulator of immunosuppression produced by arsenic and PAH co-exposures in WT mice.
While p53 and genotoxicity appear to play a central role in As3+ and PAH-induced
immunosuppression, we also have some evidence for p53-independent pathways of PAH and
As3+, based on the findings that a small percentage of TDAR immunosuppression is seen in p53
null mice. Therefore, we have considered other mechanisms for PAH and As3+ that may involve
non-genotoxic pathways (Burchiel and Luster, 2001). PAHs are substrates of peroxisases and
produce ROS generative quinone, which cause oxidative stress in the cells (Burchiel and Luster,
2001). PAHs are also able to induce Ca2+ elevation and trigger a series of downstream signaling
pathways that may lead to anergy (tolerance)(Burchiel and Luster, 2001). Recent research
showed a synthetic bioactive peptide, CKS-17, potently suppresses Th1 type immune response
by activating several intracellular signaling molecules, such as elevating intracellular cyclic
adenosine monophosphate (cAMP) levels, and inducing phosphorylation of extracellular signalregulated kinase (ERK) 1 and 2 (Haraguchi et al., 2008). A recent study showed that arsenite
induced cell cycle arrest and apoptosis in p53-proficient and p53-deficient mouse embryonic
fibroblasts (MEFs) through different mechanisms (Yu et al., 2008). In p53 +/+ MEFs, arsenite
induced alteration of genes responsible for DNA damage and cell cycle arrest, whereas in p53 -/cells, arsenite induced significant up-regulation of pro-apoptotic genes and down-regulation of
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immune modulation (Yu et al., 2008). These studies might help us better understand that while
p53 plays an important part of As3+ and PAHs induced immunosuppression, there might be more
than one mechanism responsible for xenobiotic-induced immunosuppresions.
In summary, this study utilized the TDAR to characterize the dose-dependent
immunosuppression of DMBA, DB[a,lP, BaP, their metabolites, alone or in combination with
As3+. Metabolites of PAHs were found to be more potent than parent compound. As3+ was 10fold more suppressive than As5+. In addition, As3+ at a low dose of 0.5 µM greatly potentiated
low dose PAH immunosuppression. p53 total protein expression was found to be significantly
increased by treating mouse splenocytes with these arsenic and PAHs alone or in combination. In
addition, spleen cells from p53-null mice were found in these studies to be partly protected from
As3+ and PAH immunosuppression.
Previous reports have established a positive correlation between immunosuppression
and carcinogenicity produced by genotoxic chemicals (Luster et al., 1992, 1993). However, our
data suggest that the important pathway associated with genotoxicity-induced
immunosuppression is p53. Because there is an apparent correlation between carcinogenesis and
immunosuppression produced by genotoxic chemicals (Luster et al., 1992), the question may
arise as to the role of immunosuppression in tumor formation in vivo. The immune system plays
an important role in the prevention of cancers induced by environmental chemicals, including
PAHs such as 3-methylcholanthrene (Schreiber and Pollack, 2009). A competent immune
response is required to eliminate tumor cells by recognition of the antigen expressed by tumor
cells Recent clinical and experimental studies further support this conclusion by showing that
immunosuppressants, such as cyclosporine (CsA), increase the incidence of skin cancer in organ
transplant recipients (Euvrard et al., 2004). Thus, our studies suggest that there may be common
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mechanisms of tumor induction and immunosuppression associated with the genotoxic actions of
PAHs. The genotoxicity of PAHs may be further exacerbated by co-treatments with arsenic.
While the present research provides insights into arsenic and PAHs co-exposure induced
immunosuppression, there are some limitations in this study. First, we know that an in vitro
system does not account for all of the in vivo actions of PAHs and arsenic in either animals or
humans. In the future it will be interesting to investigate the immunosuppressive mechanism(s)
produced by arsenic and PAHs using in vivo models and to evaluate their relevance to potential
human exposures. Additional studies examining potential mechanisms of As3+ and PAHs
synergistic immunosuppression will be needed in the future, including in vivo modeling of p53dependent and p53-independent pathways. These studies will help us better understand the
potential environmental risks that might be associated with human exposures and associated
immune suppression.
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LIST OF ABBRVIATIONS

2-ME

2-Mercaptoethanol

AAALAC

Association for assessment and accreditation of laboratory animal care

Ab

Antibody

ATM

Ataxia Telangiectasia Mutated protein

ATR

Ataxia Telangiectasia- and Rad3-related protein

ASTDR

Agency for Toxic Substances and Disease Registry

BaP

Benzo[a]pyrene

BSA

Bovine serum albumin

cAMP

Cyclic adenosine monophosphate

Con A

Concanavalin A

CsA

Cyclosporine

CYP

Cytochrome P450

CYP 1A1

Cytochrome P450 1A1

CYP 1B1

Cytochrome P450 1B1

DB[a,l]P

Dibenzo[a,l]pyrene

DMA

Dimethylarsenic acid

DMBA

7,12-Dimethylbenz[a]-anthracene

DMBA-diol

7,12-Dimethylbenz[a]-anthracene-3,4-dihydrodiol

DPBS

Dulbecco’s phosphate buffered saline
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DTT

Dithiothreitol

EDTA

Ethylenediamine tetraacetate acid

ERK

Extracellular signal-regulated kinase

FBS

Fetal bovine serum

GSH

Glutathione

HBSS

Hanks Balanced Salt Solution

HRP

Horseradish peroxidase

IgG

Immunoglobulin G

LPS

Lipopolysaccharide

MEFs

Mouse embryonic fibroblasts

mEH

Microsomal epoxide hydrolase

MMA

Monomethylarsenic acid

NADPH

Nicotinamide adenine dinucleotide phosphate

NOS

Nitric oxide synthase

PAHs

Polycyclic Aromatic Hydrocarbons

PARP

Poly (ADP-ribose) Polymerase-1

PFC

Plaque-forming cell assay

PM

Particulate matter

PMSF

Phenylmethylsulfonyl fluoride

RPMI

Rowell Park Memorial Institute

SDS

Sodium dodecyl sulfate

SEM

Standard error of mean
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SRBC

Sheep red blood cell

TBS

Tris-buffered saline

TBS/T

Tris-buffered saline with Tween 20

TMAO

Trimethylarsine oxide

Tris

Tris (hydroxymethyl) aminomethane

UV

Ultraviolet

WT

Wild-type
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